Cell line · CVCL_H717
Papers28
6 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 28
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical evaluation of nitrated α-synuclein-specific CAR-Treg therapy in Parkinson's disease. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Development of CAR T Cells Targeting a Surface RNA-Binding Protein for the Treatment of Acute Leukemias. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted citrullination enables p53 binding to non-canonical sites. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers. | EMBO Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. | Nat Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Natural Killer Cell-Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A timed epigenetic switch balances T and ILC lineage proportions in the thymus. | Development | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Placental co-transcriptional activator Vestigial-like 1 (VGLL1) drives tumorigenesis via increasing transcription of proliferation and invasion genes. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Induction of immortal-like and functional CAR T cells by defined factors. | J Exp Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Lymph Node-Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Five Inhibitory Receptors Display Distinct Vesicular Distributions in Murine T Cells. | Cells | 2023 | Its Methods give the RRID and name the line | PubMed | |
| TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 37503045 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors. | Cancer Immunol Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8+ T cell function and anti-tumor immunity. | Immunity | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_H717/papers